CoChat

Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial

REES, J · 1986 · The Lancet

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Between 1978 and 1983, 1127 patients with de-novo acute myeloid leukaemia (AML) were entered into the Medical Research Council (MRC)'s 8th AML trial. All received the same induction therapy consisting of daunorubicin, cytarabine, and 6-thioguanine--DAT (1 + 5). The 67% who entered complete remission were randomised to consolidation with two or six further courses of DAT. Adults under the age of 55 were randomised for central nervous system (CNS) prophylaxis with intrathecal cytarabine and methotrexate. Finally, those still in remission after 1 year of cytarabine and 6-thioguanine (AT) maintenance were randomised to receive either late intensification with cyclophosphamide, vincristine, cytarabine, and prednisolone (COAP) or continued AT. The median survival for the whole group was 12 months; the median duration of first remission was 15 months, with relapse-free survival at 5 years estimated at 18%. The factors most strongly associated with poor survival were performance status and age at presentation, but even among those over 60 years of age, half went into remission. Six courses of DAT consolidation gave a small advantage over two courses in reducing the number of late relapses but no significant survival advantage. Late intensification showed a marginally significant advantage over continued AT maintenance. The incidence of CNS relapse was low and unaffected by prophylaxis. The second remission rate varied from 10% when the first remission was shorter than 6 months to 61% when it had continued for more than 2 years. 40 patients received histocompatible allogeneic bone-marrow transplants in first remission. There was a high procedure-related death rate, particularly among patients over 30 years of age. Thus, initially at least, the transplanted group had shorter survival than a comparable group of chemotherapy-treated patients. Treatment specifications remained unchanged throughout the trial but those enrolled in the later half of the trial had a better (p = 0.003) survival.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(86)92674-7

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Cited by

See all 320

Metadata

Authors
REES, J.
Affiliations
Medical Research Council (GB)
Corresponding author
REES, J
Venue
The Lancet
Publisher
Elsevier BV
Published
1986-11
Volume
328
Issue
8518
Pages
1236-1241
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2000838340
Cited by
320
References
25
Citations by year
2026: 1 · 2025: 1 · 2024: 5 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 3 · 2016: 5 · 2015: 3 · 2014: 6 · 2013: 3 · 2012: 1
FWCI
10.21
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
  • Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Keywords
acute myeloid leukemia, consolidation chemotherapy, CNS prophylaxis, maintenance chemotherapy, allogeneic bone marrow transplantation, relapse-free survival, prognostic factors, performance status, age at presentation, non-relapse mortality
MeSH terms
Adolescent, Adult, Age Factors, Aged, Antineoplastic Combined Chemotherapy Protocols, Central Nervous System Diseases, Child, Child, Preschool, Clinical Trials as Topic, Cytarabine, Daunorubicin, Drug Administration Schedule, Humans, Infant, Middle Aged, Neoplasm Recurrence, Local, Neoplasms, Prognosis, Random Allocation, Thioguanine, Leukemia, Myeloid, Acute, Bone Marrow Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial. https://app.cochat.ai/papers/10.1016/s0140-6736(86)92674-7
The paper
REES, J. (1986). Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial. The Lancet. https://doi.org/10.1016/s0140-6736(86)92674-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.